Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas [Sarcomas]

Conclusion
This study confirms that adjuvant imatinib has an overt impact on RFS. No significant difference in IFFS was observed, although in the high-risk subgroup there was a trend in favor of the adjuvant arm. IFFS was conceived as a potential end point in the adjuvant setting because it is sensitive to secondary resistance, which is the main adverse prognostic factor in patients with advanced GIST.

Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Authors: Casali, Le Cesne, Poveda Velasco, Kotasek, Rutkowski, Hohenberger, Fumagalli, Judson, Italiano, Gelderblom, Adenis, Hartmann, Duffaud, Goldstein, Broto, Gronchi, Dei Tos, Marreaud, van der Graaf, Zalcberg, Litiere, Blay Tags: Surgery, Chemotherapy, Combined Modality Sarcomas Source Type: research